The Europe diabetic retinopathy market is projected to grow from USD 2.53 billion in 2025 to around USD 4.62 billion by 2035, expanding at a CAGR of 6.20%. Growth is driven by the rising prevalence of diabetes, increasing awareness of eye health, and advancements in retinal imaging and treatment technologies.

Europe Diabetic Retinopathy Market Statical Scope

The governments across Europe and Central Asia adopted a new WHO strategy to give every child and adolescent a healthy start in life. This new strategy invites countries to strengthen social policies and health systems that support families and children. It urges governments to promote preventive healthcare and provide high-quality and comprehensive services. This strategy also promotes health equity and inclusion, mental health, safe and supportive environments, digital well-being, participation, and empowerment.

Europe Diabetic Retinopathy Market Share, By Type, 2025 (%)

• Non-proliferative Diabetic Retinopathy (NPDR)- The non-proliferative diabetic retinopathy segment accounts for a major revenue share of 68%, owing to the primary goal of this treatment to prevent vision-threatening complications and slow progression.
• Proliferative Diabetic Retinopathy (PDR)- The proliferative diabetic retinopathy segment holds a share of 32%, due to the urgent need for treating this advanced and more severe stage of diabetic eye disease.

Europe Diabetic Retinopathy Market Share, By Management, 2025 (%)

• Anti-VEGF- The anti-VEGF segment occupies a share of 46%, driven by this highly effective and first-line management therapy for diabetic macular edema and proliferative diabetic retinopathy.
• Intraocular Steroid Injection- The intraocular steroid injection segment drives a share of 22%, supported by its potential to treat conditions like retinal vein occlusion, diabetic macular edema, uveitis, and swelling following eye surgery.
• Laser Surgery- The laser surgery segment is seen to hold a share of 18%, surging due to the importance of this minimally invasive medical procedure in reducing swelling, blood loss, and recovery time.
• Vitrectomy- The vitrectomy segment is observed to expand with a share of 14%, accelerated by its use in advanced and severe cases involving retinal complications and vision-threatening conditions.

Top Companies in the Europe Diabetic Retinopathy Market

• Bayer AG
• AbbVie Inc.
• Novartis AG
• Oxurion NV.
• Sirnaomics
• Alimera Sciences
• Ampio Pharmaceuticals Inc.
• BCNPeptides
• Kowa Company, Ltd.
• Genentech, Inc.

Segments Covered in the Report

By Type

• Proliferative Diabetic Retinopathy
• Non-proliferative Diabetic Retinopathy

By Management

• Anti-VEGF
• Intraocular Steroid Injection
• Laser Surgery
• Vitrectomy